



Virus-Like Particles in Vaccine and Cancer Immunotherapy

Guest Editor:

Prof. Dr. Qizhi Cathy Yao

1. Michael E. DeBaakey
Department of Surgery, Division
of Surgical Oncology, Baylor
College of Medicine, Houston, TX
77030, USA
2. Center for Translational
Research on Inflammatory
Diseases (CTRID), Michael E.
DeBaakey VA Medical Center,
Houston, TX 77030, USA

Deadline for manuscript
submissions:
closed (31 January 2024)

Message from the Guest Editor

Virus-like particles (VLPs) are replication-incompetent vaccines that represent an intact, non-replicative virion lacking a genome but maintaining the original antigenic composition of the surface proteins incorporated into the virion's outer membrane. VLPs have unique properties as particulate immunogens due to their size and pseudoviral structure, which may correctly present linear and conformational epitopes to the immune system to elicit both humoral and cellular immune responses. Therefore, it is an attractive approach and has been widely used for infectious disease vaccines and for cancer immunotherapies.

This Special Issue focuses on "Virus-like Particles in Vaccine and Cancer Immunotherapy". Submissions of original articles, systematic reviews, short communications, and other types of articles on related topics are welcome. All manuscripts will follow standard journal peer-review practices, and those accepted for publication will appear in the issue "Virus-like Particles in Vaccine and Cancer Immunotherapy". We look forward to receiving your contributions to the Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com